Generate your single-domain antibodies (VHH) in 6 weeks using AI and biological tools, for impactful research.
IMMUNOCHEM’s EVOBodies™ platforms works from any antigen, even toxic or non-immunogenic ones. We offer AI-constructed VHH to help Scientific Managers in Bio-Pharmaceutical companies streamline their processes, get rid off time spent on unpredictability, and achieve the results they deserve.
Our trusted partners
Are you struggling to generate reliable and precise antigen-binding molecules?
Are you frustrated by the complexity and difficulty of generating precise antibodies against your targets?
Are you tired of time-consuming mAbs generation campaigns and betting on uncertain immunization results?
Are you part of the 86% of labs suffering from the lack of reproducibility?
Are you concerned that unreliable antibodies could jeopardize your entire research project, wasting months or even years of work?
If you answered yes to at least one of those questions, take a moment to read on to discover how EVOBodies™ can help.
We know how it feels to lose time, energy, and resources, ending up exhausted with inconclusive results.
Before beeing experts, we also struggled to find solutions by ourselves. We imagined, explored and tested various existing methods, including immunization in mice, rats, and rabbits. We also attempted recombinant expression in CHO and HEK cells. We even tested exotic methodology such as those you read in the litterature but which never works.... ... And nothing came out.
We felt anxious and frustrated, with the intense stress brought on by the relentless pressure of our Board, Managers, competitors and the looming deadlines for publication. Each passing day without certainty increased that stress, making it harder to stay focused and motivated. We gradually lost faith in our project, and even worth, in our self-confidence. Our initial enthusiasm was overshadowed by doubt, making it challenging to believe in the potential success of our project.
While the solution was there, under our eyes since the begining : we decided to stop relying on the slow and random process which comes from immunisation and start relying on manageable and predictable AI-based biology.
We are Scientific Entrepreneurs. We understand the economic vision behind your project.
You shouldn’t struggle to generate antigen-binding molecule as starting materials for your crucial research. Unpredictable solutions shouldn't compromise your work. Through EVOBodies™ platform, IMMUNOCHEM provides precise AI-driven antibody discovery, helping bio-pharmaceutical managers and scientists save time, reduce stress, and achieve the groundbreaking research results they deserve.
What if you could create your tailored antibody with controllable, predictable AI-based biology?
Now, imagine you are working without the stress incumbent upon chance-relying results. Because your antigen-binding molecule are no longer the outcome of trial and error, but the result of deliberate, intentional design, built to match your needs.
From now, you own the perfect material to target and detect your antigens and you perform your experiments with high-reproductibility.
Visualize your science moving forward in flow. You are waiting confident the end of your day experience. Your missing experiences are not any more a conversation subject since you conquer your antibody construction.
You take pleasure in your science. And you can finally allocate more of your time to strategy instead of energy-consuming failing experiment.
How single-domain antibodies and minibinders are a game-changer for your projects ?
Single-domain antibodies or VHH are the equivalent of the variable domain of camelid heavy chain-only IgGs (HCAb). Being only 15kDa, they offer significant advantages in research and therapeutic applications.
Minibinders, on the other hand, are fully engineered proteins designed from scratch using computational models to replicate and enhance the binding function of antibodies.
Together, VHHs and minibinders represent the most advanced generation of binding proteins — combining biological robustness with rational design. Both formats provide unmatched access to complex, constrained or unpredictable molecular targets.
As ultra-compact binding entities, they reach epitopes that are inaccessible to conventional antibodies. Their structural simplicity and robustness make them ideal tools for research, diagnostics and next-generation therapeutics.
Working with VHHs and minibinders means choosing a controlled, faster and more reliable path to discovery, free from the uncertainty of traditional antibody development.
Here’s why working with VHH and minibinders is a great choice for your research
Predictable : VHHs and minibinders are selected or designed using structure-driven and AI-powered workflows, offering a reproducible and rational development process.
Efficient : VHHs and minibinders eliminate the need for immunization and blind screening, drastically shortening timelines from target to functional binder.
Simple : VHHs and minibinders are fully compatible with recombinant expression systems, enabling fast production and straightforward scaling.
Small : VHHs and minibinders reach cryptic or buried epitopes that are inaccessible to conventional antibodies and display superior tissue penetration.
Stable: VHHs and minibinders maintain activity under demanding experimental conditions, ensuring long-term reliability and shelf-life stability.
Easy to engineer : VHHs and minibinders are fully sequence-defined, modular and customizable, enablintg optimization, integration and IP protection.
Leveraging Artificial Intelligence for enhanced antibody and VHH solutions
Today, by combining AI and biological tools, you have the power in your hand to create your tailored antibodies in only a few weeks, rather than waiting months for unpredictable results from traditional immunization processes.
What's even better for you? This method works for any antigen, including:
little or non-immunogenic
toxic to the host
highly conserved
targeting vital functions
Using Artificial Intelligence to design VHHs and minibinders means :
You don’t need the physical antigen.
You built everything from scratch from its sequence (de novo generation).
You accelerate your pipeline for developing therapeutic antibodies.
You improve the developability of your molecules.
You own detailed reports of AI analyses that predict the characteristics of your VHH.
Take advantage of the VHH and minibinders technology in your own field of applications
In Biotech & Pharma
- Target specific antigens that were impossible or difficult-to-access targets
- Switch from mAbs to VHH and minibinders as molecules with numerous advantages
- Benefit from easy scale-up and reproducibility
In diagnostics
- Switch your polyclonal antibody to VHH or minibinders for more robust process
- Design precise pairs of molecules for your tests (CLIA, ELISA, LFA, etc.)
- Increase the sensitivity of your tests
In R&D
- Discover totally new molecules again your antigen
- Realize experiments with VHH and minibinders even in the hardest conditions
- Reach cryptic or hidden antigens, identify conformational changes or idiotypes with precisely designed VHHs and minibinders.
Create your VHH and minibinders in 6 weeks effortlessly with our unique EVOBodies™ program
If you want to generate highly precise molecules, that will significantly impact your scientific developments, you can count on IMMUNOCHEM’s EVOBodies™ platform to help you succeed.
Define your antigen precisely
Select the antigen and the antigen sequence of interest.
Receive 3D VHH or minibinders structure
Receive the generated sequence along with a brief report, including its 3D structure visualization.
Get your validated and expressed VHH or minibinders to start your experiment directly
Receive the synthesized and validated VHH, ready to perform precise and reliable assays in your lab.
Meet Philippe Herman, CEO of Immunochem and passionate innovator in Life Sciences
Hello, I’m Philippe Herman ! I have been evolving for +12 years on the intersection of biophysics and computational biology.
I authored 20 papers studying microbial adhesion using the atomic force microscope. I had the chance to apply it to the fabulous world of microbes. I discovered and demonstrated key concepts in protein-host protein interactions for staphylococcal proteins. I notably wrote a PNAS paper in 2018 and was invited to write a Science perspective around the hospital-acquired infections.
I am passionate about how technique can help Science. During my research, I needed of precisely designed molecules against my antigens of interests.
This led me to discover the power of VHH and minibinders, and inspired me to develop IMMUNOCHEM’s EVOBodies™ platform, making it accessible to our clients.
“I am committed to brigging the best solutions that shape the future of healthcare”
I am always eager to connect and assist professionals sharing a passion for biotechnology, driven to make an impact using Science.
Conduct innovative research for significant medical advancement by getting rid of unreliable materials or missed deadlines.
Predictable results
AI-driven discovery is the most optimal tool to design precisely any antigen-binding molecules such as VHHs and minibinders.
Save time on discovery process
Meet your deadlines thanks to our 6-week EVOBodies™ program. Keep your focus on the innovative aspects of your research, and leave stress behind.
No more animals
Receive the synthesized and validated VHH and minibinders, ready to perform precise and reliable assays in your lab.
How to start your journey with IMMUNOCHEM to create your Single-Domain Antibodies (VHH) in 6 weeks ?
Take advantage of your EVOTwice warranty
To show you the confidence we have in our EVOBodies ™ platform, and for a limited time only, we offer to our new customers the EVOTwice warranty. If the VHH do not bind your target in your assay, we commit to a second round of EVOBodies™program at no cost, ensuring you have a reliable outcome.
Frequently asked questions
You will receive your VHH ready-to-test between 6 to 8 weeks after contract signature and kick-off meeting.
Antigen sequence is enough. But you may need the antigen at your disposal for validity testing in your lab.
After our kick-off meeting, the first phase will consist of generating a 3D structure of VHHs against your antigen of interest. If we consider the chance are low to generate a good binder, we won’t move forward.
IMMUNOCHEM is a company founded in 1998, preliminary providing a catalog of high quality antibody. Since 2020, the company specialises on VHH discovery and generation, leveraging biological as well as AI tools.
Through our EVOTwice™ warranty, we commit to pursue another round of VHH generation if you demonstrate that the VHH does not eventually perform correctly in your binding assay.
IMMUNOCHEM positions as a key partner in the discovery phases including VHH generation at small scale. For intence production, we will gladly suggest you some of our reliable partners.
If your country allows the reception of biologics, it means that we can work together
Still have a question?
If you need more information, please email us or book your discovery call.
If you want to achieve your scientific goals, you know there are only two possible choices.
The first choice is to continue as you always have.
Trying to generate antibodies through immunization without certainty about the molecules obtained, wasting money transferring your sequences for recombinant expression in sometimes exotic cells, and secretly envying those who easily generate their molecules of interest.
You are free to waste your time and continue to dream.
Or you have this second choice.
To invest in our EVOBodies™ program, to experience concrete scientific developments by generating your VHH in 6 weeks.
Against even the most complex targets.
Without randomness.
And become the leader who reassures his teams by his ability to identify solutions that lead research to success.
You are free to invest now to finally achieve your company's scientific objectives.
And with our EVOTwice warranty, you take no risk.
We know you can succeed by following a controlled process, like the other clients who trust us.
Start relying on predictable solutions to develop your processes with serenity
Apply for access to our VHH-testing group and receive a 3D visualization of your single-domain antibody against any antigen of interest. Currently, this service is free of charge for a limited number of participants